COVID-19 Update: See the latest on our visitor policy here. Learn More
Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to test the safety and tolerability of intratumoral administration of MEM-288 in participants with NSCLC, cutaneous squamous-cell carcinoma (cSCC), Merkel cell, melanoma, triple negative breast cancer (TNBC), pancreatic cancer, or head and neck cancer tumors that have spread.
Primary Objectives: 1. To determine the safety, tolerability, and maximum tolerated dose (MTD) of intratumoral administration of MEM-288 as a single agent. Secondary Objectives: 1. To assess efficacy overall response rate in a variety of solid tumors, as well as disease control rate, progression free survival and duration of response. 2. To evaluate anti-tumor immune responses of intratumoral MEM-288 single agent by evaluating biopsy tissue of injected lesions and serial blood draws.
MEM-288 (); Pembrolizumab (Keytruda)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.